Skip to main content
Caplight Logo









Serca Pharmaceuticals

Serca Pharmaceuticals

Private
OsloHealthcare & Life Scienceshttps://sercapharmaceuticals.com/

Last Round

Grant

Jan 1, 2025

Total Funding Raised

$3.71M

Company Overview

Serca Pharmaceuticals is a biopharmaceutical company developing a novel cardioprotective drug candidate, 13-M, for the treatment of acute myocardial infarction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalcardioprotective drugacute myocardial infarctionheart attack treatmentsmall molecule drugischemic reperfusion injurypercutaneous coronary interventionPCIdrug developmentcardiac therapybiotech startupclinical trialsheart failure preventiondrug licensingpre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Serca Pharmaceuticals Comparables

Compare Serca Pharmaceuticals with similar companies based on industry and business-model similarity.

Serca Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Orio Therapeutics SA
85%
Forcefield Therapeutics
81%
Infensa Bioscience
79%

Serca Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 1, 2025
GrantOct 1, 2020
VC RoundJul 1, 2019

Serca Pharmaceuticals Investors

Notable investors and investment history

Serca Pharmaceuticals investors
InvestorRounds
Inven2VC Round
SarsiaVC Round
The Research Council of NorwayGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors increased 80% MoM.

  • Oct 19, 2024

    Grew 400% QoQ from 1 to 5 employees.

Serca Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Serca Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Serca Pharmaceuticals's valuation, stock price, and market status.

Is Serca Pharmaceuticals a public or private company?

Serca Pharmaceuticals is a private company.

What is the current stock price of Serca Pharmaceuticals?

Serca Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Serca Pharmaceuticals worth (valuation)?

Valuation information for Serca Pharmaceuticals is not publicly available.

Can I buy Serca Pharmaceuticals stock?

Serca Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Serca Pharmaceuticals's last funding round?

Serca Pharmaceuticals's most recent funding round was Grant on January 1, 2025.

Who are the main investors in Serca Pharmaceuticals?

Key investors in Serca Pharmaceuticals include Inven2, Sarsia, The Research Council of Norway.

Will Serca Pharmaceuticals IPO soon?

No public IPO plans have been announced for Serca Pharmaceuticals.

How can I track Serca Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Serca Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOslo
Employee Range2
Year Founded2018
Last FundingJan 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?